Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...

Commercial partner Ascensia is in discussions with insulin pump manufacturers to create an automated insulin delivery system.

The transmitter is placed on the skin on top of the implanted sensor ... integrate with compatible medical devices, including insulin pumps, as part of an automated insulin delivery system.

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...

Medtronic, a global developer and manufacturer of medical devices for chronic diseases, is now a $111 billion (by market cap) ...

Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus ...

The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable ...

Senseonics, a medtech manufacturer developing long-term, implantable continuous glucose monitoring (CGM) systems, and ...

Every year our editors hit the gas to bring you the GQ Fitness Awards. We sweat the small stuff when it comes to performance fabrics, fitness watches, running shoes, protein powders, recovery tools, ...